Therapeutic drug management of linezolid: a missed opportunity for clinicians?

International Journal of Antimicrobial Agents

Volumn 48, Issue 6, 2016, Pages 728-731

  Cattaneo, Dario ^a   Gervasoni, Cristina ^a   Cozzi, Valeria ^a   Castoldi, Simone ^a   Baldelli, Sara ^a   Clementi, Emilio ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Bacterial infection; Interindividual variability; Linezolid; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

CREATININE; LINEZOLID; ANTIINFECTIVE AGENT;

ADULT; AGE; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HUMAN; ITALY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PHYSICIAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEADY STATE; VERY ELDERLY; BACTERIAL INFECTIONS; CHEMISTRY; MIDDLE AGED; PROCEDURES; SERUM; UTILIZATION;

AGE FACTORS; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HUMANS; ITALY; LINEZOLID; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SERUM;

EID: 85000983855     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.08.023     Document Type: Article

References (20)

1. [1] Di Paolo, A., Malacarne, P., Guidotti, E., Danesi, R., Del Tacca, M., Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet 49 (2010), 439–447.
2. [2] Dryden, M.S., Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 66:Suppl. 4 (2011), iv7–15.
3. [3] Cattaneo, D., Alffenaar, J.W., Neely, M., Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. Expert Opin Drug Metab Toxicol 12 (2016), 533–544.
4. [4] Matsumoto, K., Shigemi, A., Takeshita, A., Watanabe, E., Yokoyama, Y., Ikawa, K., et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents 44 (2014), 242–247.
5. [5] Abe, S., Chiba, K., Cirincione, B., Grasela, T.H., Ito, K., Suwa, T., Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol 49 (2009), 1071–1078.
6. [6] Morata, L., De la Calle, C., Gómez-Cerquera, J.M., Manzanedo, L., Casals, G., Brunet, M., et al. Risk factors associated with high linezolid trough plasma concentrations. Expert Opin Pharmacother 17 (2016), 1183–1187.
7. [7] Ichie, T., Suzuki, D., Yasui, K., Takahashi, H., Matsuda, M., Hayashi, H., et al. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis. J Clin Pharm Ther 40 (2015), 279–284.
8. [8] Cattaneo, D., Orlando, G., Cozzi, V., Cordier, L., Baldelli, S., Merli, S., et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with Gram-positive infections. Int J Antimicrob Agents 41 (2013), 586–589.
9. [9] Nukui, Y., Hatakeyama, S., Okamoto, K., Yamamoto, T., Hisaka, A., Suzuki, H., et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother 68 (2013), 2128–2133.
10. [10] Pea, F., Viale, P., Cojutti, P., Del Pin, B., Zamparini, E., Furlanut, M., Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 67 (2012), 2034–2042.
11. [11] Dong, H., Xie, J., Chen, L., Wang, T., Sun, J., Zhao, Y., et al. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients. Int J Infect Dis 22 (2014), 35–40.
12. [12] Boak, L.M., Rayner, C.R., Grayson, M.L., Paterson, D.L., Spelman, D., Khumra, S., et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother 58 (2014), 2334–2343.
13. [13] Song, T., Lee, M., Jeon, H.S., Park, Y., Dodd, L.E., Dartois, V., et al. Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis. EBioMedicine 2 (2015), 1627–1633.
14. [14] Cattaneo, D., Baldelli, S., Conti, F., Cozzi, V., Clementi, E., Determination of linezolid in human plasma by high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 32 (2010), 520–524.
15. [15] Douros, A., Grabowski, K., Stahlmann, R., Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol 11 (2015), 1849–1859.
16. [16] Gervasoni, C., Bergia, R., Cozzi, V., Clementi, E., Cattaneo, D., Is it time to revise linezolid doses in peritoneal dialysis patients? A case series. J Antimicrob Chemother 70 (2015), 2918–2920.
17. [17] Hiraki, Y., Tsuji, Y., Hiraike, M., Misumi, N., Matsumoto, K., Morita, K., et al. Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis 44 (2012), 60–64.
18. [18] Neely, M., Jelliffe, R., Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol 48 (2008), 1081–1091.
19. [19] Huang, Y., Shi, R., Gee, W., Bonderud R. Regulated drug bioanalysis for human pharmacokinetic studies and therapeutic drug management. Bioanalysis 4 (2012), 1919–1931.
20. [20] Lavine, G., Pharmacogenetics, therapeutic drug management offer new insights into treating pain. Am J Health Syst Pharm 65 (2008), 1588–1590.